State of metabolic processes and ways to improve them in premenopausal women due to the life extension strategy




perimenopause, Xylat, Tivortin, antiaging, life extension


Increasing the duration and improving the quality of life of older women is a significant problem of current medicine. Metabolic disorders in the form of type II diabetes mellitus and atherogenic dyslipidemia lead to a significant level of cardiovascular complications. It is known that hormone replacement therapy cannot normalize age-related metabolic disorders. Therefore, the search for new methods of cardiovascular health is extremely relevant.
Research objective: to study the state of autonomic nervous regulation, carbohydrate and lipid metabolism in perimenopausal women using the life extension approach.
Materials and methods. Group I (control) consisted of 35 apparently healthy women of reproductive age. Group II (main) consisted of 71 patients whom was administered a solution of xylitol with electrolytes (Xylate) by infusion from the first days of the reduction diet for 5 days, and also L-arginine (Tivortin) was injected intravenously for 5 days, 200 ml once a day, followed by taking a drinking solution of this drug for another three weeks. All patients followed a 28-day diet, and also performed daily aerobic morning exercises for 3 months.
Results. A significant decrease in body mass index in patients of the main group due to the proposed treatment and prevention program was found. At the same time, Kupperman index declined significantly. Decreased body mass index in patients of the main group was the basis for improved autonomic nervous regulation and metabolic processes. Xylate-Tivortin complex has allowed emphasizing the overcoming of insulin resistance, dyslipidemia and chronic inflammation.
Conclusions. The developed 3-month program allowed to significantly improving the metabolic processes and hemodynamic parameters in women of perimenopausal age. This is the basis for the introduction of Xylate-Tivortin complex life extension into the practice of family physicians, obstetricians and gynecologists and specialists in the field of aesthetic medicine.

Author Biography

I.V. Lakhno, V.N. Karazin Kharkiv National University, Kharkiv

MD, professor, Department of Obstetrics and Gynecology


  1. Paciuc, J. “Hormone Therapy in Menopause.” Adv Exp Med Biol 1242 (2020): 89–120. DOI: 10.1007/978-3-030-38474-6_6
  2. Glintborg, D., Rubin, K.H., Nybo, M., et al. “Cardiovascular disease in a nationwide population of Danish women with polycystic ovary syndrome.” Cardiovasc Diabetol 7 (2018): 37. DOI: 10.1186/s12933-018-0680-5
  3. Nair, A.R., Pillai, A.J., Nair, N. “Cardiovascular Changes in Menopause.” Curr Cardiol Rev 17.4 (2021): e230421187681. DOI: 10.2174/1573403X16666201106141811
  4. Newson, L. “Menopause and cardiovascular disease.” Post Reprod Health (24) 2018: 44–9. DOI: 10.1177/2053369117749675
  5. El Khoudary, S.R. “Age at menopause onset and risk of cardiovascular disease around the world.” Maturitas 141 (2020): 33–3. DOI: 10.1016/j.maturitas.2020.06.007
  6. El Khoudary, S.R. “HDL and the menopause.” Curr Opin Lipidol 28 (2017): 328–36. DOI: 10.1097/MOL.0000000000000432
  7. Stuenkel, C.A. “Menopause, hormone therapy and diabetes.” Review Climacteric 20 (2017): 11–21. DOI: 10.1080/13697137.2016.1267723
  8. Hoyer, D., Zebrowski, J., Cysarz, D., et al. “Monitoring fetal maturation-objectives, techniques and indices of autonomic function.” Physiol Meas 38 (2017): 61–88. DOI: 10.1088/1361-6579/aa5fca
  9. Shufelt, C.L., Pacheco, C., Tweet, M.S., Miller, V.M. “Sex-Specific Physiology and Cardiovascular Disease.” Adv Exp Med Bio 1065 (2018): 433–54. DOI: 10.1007/978-3-319-77932-4_27
  10. Frungieri, M.B., Calandra, R.S., Bartke, A., Matzkin, M.E. “Male and female gonadal ageing: its impact on health span and life span.” Mech Ageing Dev 197 (2021): 111519. DOI: 10.1016/j.mad.2021.111519
  11. Somani, Y.B., Pawelczyk, J.A., De Souza, M.J., et al. “Aging women and their endothelium: probing the relative role of estrogen on vasodilator function.” Am J Physiol Heart Circ Physiol 317 (2019): H395–404. DOI: 10.1152/ajpheart.00430.2018
  12. Berikhanova, R.R., Minenko, I.A., Bondarev, S.A. “Carbohydrate metabolism in women with metabolic syndrome with multimodal non-drug correction of menopausal disorders.” Arch Gerontol Geriatr 28 (2020): 104205. DOI: 10.1016/j.archger.2020.104205
  13. Geidenstam, N., Al-Majdoub, M., Ekman, M., et al. “Metabolite profiling of obese individuals before and after a one year weight loss program (Observational Study).” Int J Obes (Lond) 41 (2017): 1369–78. DOI: 10.1038/ijo.2017.124
  14. Benahmed, A.G., Gasmi, A., Arshad, M., et al. “Health benefits of xylitol.” Appl Microbiol Biotechnol 104 (2020): 7225–37. DOI: 10.1007/s00253-020-10708-7
  15. Lakhno, I. “Possibilities of xylitol and L-arginine usе in menopause management.” Reproductive health of woman 2 (2021): 64–8. DOI: 10.30841/2708-8731.2.2021.232554
  16. Sari, I.K., Utari, D.M., Kamoshita, S., et al. “Increasing vegetable intake 400 g/day to control body weight and lipid profile in overweight hyperlipidemia menopausal women.” J Public Health Res 9 (2020): 1733. DOI: 10.4081/jphr.2020.1733
  17. Chalwe, J.M., Mukherjee, U., Grobler, C., et al. “Association between hypertension, obesity and dietary intake in post- menopausal women from rural Zambian communities.” Health SA 26 (2021): 1496. DOI: 10.4102/hsag.v26i0.1496
  18. Biglia, N., Cagnacci, A., Gambacciani, M., et al. “Vasomotor symptoms in menopause: a biomarker of cardiovascular disease risk and other chronic diseases?” Climacteric 20 (2017): 306–12. DOI: 10.1080/13697137.2017.1315089
  19. Klawitter, J., Hildreth, K.L., Christians, U., et al. “A relative L-arginine deficiency contributes to endothelial dysfunction across the stages of the menopausal transition.” Physiological Reports 5 (2017): e13409.
  20. Puga, G.M., Novais, I.P., Katsanos, C.S., et al. “Combined effects of aerobic exercise and l-arginine ingestion on blood pressure in normotensive postmenopausal women: A crossover study Randomized Controlled Trial.” Life Sci 151 (2016): 323–9. DOI: 10.1016/j.lfs.2016.02.091
  21. Minkin, M.J. “Menopause: Hormones, Lifestyle, and Optimizing Aging.” Obstet Gynecol Clin North Am 46 (2019): 501–14. DOI: 10.1016/j.ogc.2019.04.008
  22. Rivolta, M.W., Stampalija, T., Frasch, M.G., et al. “Theoretical value of Deceleration Capacity Points to Deceleration Reserve of Fetal Heart Rate.” IEEE Trans Biomed Eng 67 (2020): 1176–85. DOI: 10.1109/TBME.2019.2932808
  23. Rangel-Huerta, O.D., Pastor-Villaescusa, B., Gil, A. “Are we close to defining a metabolomic signature of human obesity? A systematic review of metabolomics studies.” Metabolomics 15.93 (2019).
  24. Kim, C. “Management of Cardiovascular Risk in Perimenopausal Women with Diabetes.” Diabetes Metab J 45 (2021): 492–501. DOI: 10.4093/dmj.2020.0262
  25. Davydova, Y.V., Limanskaya, A.Y., Tuday, V.N., Mokrik, A.N. “Clinical case of Xylat use in the complex therapy of severe early toxicosis of pregnant women.” Health of Woman 1 (2015): 45–8.



How to Cite

Lakhno, I. (2021). State of metabolic processes and ways to improve them in premenopausal women due to the life extension strategy. REPRODUCTIVE ENDOCRINOLOGY, (61), 51–54.